EN
Patient-first cell therapy innovation
 
TCR repertoire characteristics predict clinical response to adoptive CTL therapy against nasopharyngeal carcinoma.
  • 0
Wang G., Mudgal P., Wang L., Shuen T.W.H., Wu H., Alexander P.B., Wang W.W., Wan Y., Toh H.C.*, Wang X.-F.*, and Li Q.-J.* (2021) TCR repertoire characteristics predict clinical response to adoptive CTL therapy against nasopharyngeal carcinoma. Oncoimmunology. 10(1):1955545. (*: Corresponding authors, PMCID: PMC8331028)

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8331028/

Copyright © 2019 TCR CURE Biopharma Technology Co., Ltd Powered by vancheer
About TCRCure
Research and Development
Products and Clinic
News and Media
Recruitment

Copyright © 2019 TCR CURE Biopharma Technology Co., Ltd Powered by vancheer